CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Team InterventionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D019966 Substance-Related Disorders NIH 0.33

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Multi-Tiered Safety Net Following Naloxone Resuscitation From Opioid Overdose

The principal aim of this study is to determine whether a novel biopsychosocial intervention following opioid overdose (OD) affects 1) the frequency of secondary opioid OD events and 2) the proportion of individuals who remain engaged in treatment for opioid use disorder (OUD) or are in remission at 30 days and at 180 days post intervention. Remission is defined as engagement in daily medication-assisted therapy (MAT)—typically buprenorphine/naloxone (BUP) or methadone— and/or a recovery capital score of ≥ 27.5. The intervention principally involves connecting OUD-affected individuals with community resources, including BUP-, MAT-, and education-related services. To carry out the intervention, an addiction recovery coach and an appropriately trained health-educator paramedic (research assistant) will form a team and perform follow-up visits (electronically/remotely and/or by phone) after a participant has experienced at least 1 opioid OD requiring naloxone resuscitation. Our hypothesis is that the intervention will decrease subsequent OD events and increase the likelihood of remission. To evaluate this hypothesis, data will be collected from self-report and from EPIC, Yale New Haven Hospital's medical record system. The secondary aim is to determine whether the intervention affects 1) the frequency of positive-urine tests for opioids and 2) the frequency and proportion of subjects self-reporting opioid use. Our hypothesis is that our intervention will decrease both. Data from the entire cohort will be compared in aggregate with patients who were started on BUP in the ED over the same time period and with historic controls.

NCT04253782 Opioid-Use Disorder (OUD) Other: Team Intervention
MeSH:Substance-Related Disorders

Primary Outcomes

Description: Frequency of positive urine tests at 30 days after intervention (data obtained via chart review)

Measure: Frequency of positive urine tests at 30 days (chart review)

Time: 30 days post intervention

Description: Frequency of positive urine tests at 180 days after intervention (data obtained via chart review)

Measure: Frequency of positive urine tests at 180 days (chart review)

Time: 180 days post intervention

Description: Frequency of positive urine tests at 30 days after intervention (data obtained via self-report)

Measure: Frequency of positive urine tests at 30 days (self-report)

Time: 30 days post intervention

Description: Frequency of positive urine tests at 180 days after intervention (data obtained via self-report)

Measure: Frequency of positive urine tests at 180 days (self-report)

Time: 180 days post intervention

Secondary Outcomes

Description: Percentage of positive urine tests at 30 days after intervention (data obtained via chart review)

Measure: Percentage of positive urine tests at 30 days (chart review)

Time: 30 days post intervention

Description: Percentage of positive urine tests at 180 days after intervention (data obtained via chart review)

Measure: Percentage of positive urine tests at 180 days (chart review)

Time: 180 days post intervention

Description: Percentage of positive urine tests at 30 days after intervention (data obtained via chart review)

Measure: Percentage of positive urine tests at 30 days (self-report)

Time: 30 days post intervention

Description: Percentage of positive urine tests at 180 days after intervention (data obtained via self-report)

Measure: Percentage of positive urine tests at 180 days (self-report)

Time: 180 days post intervention


No related HPO nodes (Using clinical trials)